Read this first.
This guide is general background for practice owners considering a transaction. It is not legal advice, it does not cover every state requirement, and requirements change frequently. Confirm your own position with your state medical board, your state nursing board, and a healthcare attorney licensed in your state before acting.
The short answer
Who can own a med spa depends on the state. Licensed physicians can own in all fifty. Nurse practitioners can in some. In restrictive states, non-physicians participate through a management services organisation alongside a physician-owned clinical entity. How that structure is documented is among the first things a buyer’s counsel examines, and among the most common reasons a deal stalls.
Quick answers
Seven narrow questions, one sentence each. These catch conversational queries that don’t warrant reading the article. Phrased deliberately differently from the FAQ at the bottom, and not included in the FAQPage schema — two Question entities sharing a name but not an answer is a quality problem.
Can a physician own a med spa anywhere in the US? Yes — licensed MDs and DOs can own in every state, and board certification in a particular specialty is generally not required.
Is the corporate practice of medicine a federal law? No — it is a state-law doctrine, and states differ substantially in how they define and enforce it.
Why do MSO structures exist at all? Because in states restricting non-physician ownership, an MSO is how non-clinical capital can participate in the business without controlling clinical decisions.
Can a registered nurse own a med spa? In many states an RN can own the business, but never the prescribing authority — an RN-owned practice always requires a prescriber relationship.
Is a medical director enough on its own? No — a named director who does not actually supervise is the single most common structural defect found in diligence.
Does a delegation order replace a good faith examination? No — the order becomes valid only once the examination is complete, and it should be specific to that patient and treatment.
Does any of this actually affect what my practice sells for? Yes — structural defects change deal terms as often as they change deal price, and occasionally end transactions entirely.
Key takeaways
- Corporate practice of medicine is a state doctrine, not a federal law, and most states still have no statutory definition of “medical spa” — so the rules governing your practice are assembled from several documents, none written with your business model in mind.
- Full practice authority and ownership eligibility are separate questions; a state can grant one and withhold the other.
- Building the wrong structure is expensive in both directions — an unnecessary friendly-PC arrangement in a permissive state wastes money and months, while skipping one in a strict state creates enforcement exposure.
- Injector authority has two distinct parts — who may order a treatment, and who may administer it — and the good faith examination is what connects them.
- Compliance defects surface in legal diligence and typically produce larger escrows, uncapped indemnity carve-outs, or a withdrawn buyer, rather than a simple price adjustment.
Why structure decides what your practice sells for
Most owners meet this subject twice. Once when they open — usually briefly, usually via a template — and once when they sell, when a buyer’s attorney reads what they signed years ago and begins asking questions.
The second occasion is considerably more expensive.
Compliance is not the interesting part of owning a practice. It is, increasingly, the part that determines whether a sale completes and on what terms. Four reasons it belongs on the value line rather than the administrative one:
The buyer inherits the risk. A structural defect does not stay behind with you. An institutional buyer acquires your practice’s history, and their counsel is paid to establish what that history contains.
It stretches the timeline. Structural questions in diligence take weeks rather than days, and they arrive when you are already exclusive and already tired.
It changes terms, not just price. A defect discovered in diligence typically produces some combination of a larger escrow, a specific indemnity carve-out with no cap, a holdback pending remediation, and a reduction. You may still close — on materially worse terms.
Sometimes it ends the deal. Some institutional buyers will not acquire a practice whose clinical structure cannot be made compliant on their timetable, at any price.
The corresponding opportunity is real, and it is unusually cheap. A practice with clean, current structural documentation is meaningfully more attractive than an identical practice without it, because it removes an entire category of risk from the buyer’s model. Of everything an owner can do to improve a valuation, this is among the least expensive and the most frequently skipped.
What is the corporate practice of medicine?
The corporate practice of medicine is a state-law doctrine restricting unlicensed individuals and corporations from owning medical practices, employing physicians, or controlling clinical decisions. It is not federal law, it varies substantially between states, and it is the reason management services organisation structures exist in medical aesthetics.
The American Bar Association’s Health Law Section identifies CPOM restrictions in more than 30 states.
The underlying principle: medical judgement should sit with licensed clinicians rather than with owners whose primary interest is financial.
What that means in practice for an aesthetics business
In a strict CPOM state, a conventional LLC cannot own the entity delivering medical services. Non-physician capital cannot employ the physician. Compensation arrangements amounting to sharing clinical revenue with an unlicensed party — fee-splitting — are restricted, sometimes severely.
Two complications specific to this sector
Aesthetic treatments are the practice of medicine. Neuromodulators, dermal fillers and many device treatments are prescription-classified or medically regulated. That is what pulls a business calling itself a “spa” inside a doctrine most owners assume applies only to clinics.
Most states have no legal definition of “medical spa.” The category exists commercially but frequently not statutorily. The rules governing you are therefore assembled from the Medical Practice Act, the Nurse Practice Act, board rules and advisory opinions — several documents, none of them written with your business model in mind.
That ambiguity is why two well-intentioned practices in the same state can be structured completely differently, and it is why buyers look closely rather than taking a structure at face value.
Who can own a med spa?
Licensed physicians — MDs and DOs — can own med spas in every US state, and board certification in a particular specialty is generally not required. Whether a nurse practitioner, registered nurse or non-clinical owner can hold the clinical entity depends on the state’s CPOM posture and its nurse practice act.
Physicians
Can own everywhere. Specialty is generally not the limiting factor legally — family medicine physicians and internists operate aesthetics practices routinely. Clinically, competence in facial anatomy and injection technique is a separate obligation from licensure, and buyers assess it separately too.
Nurse practitioners
Approximately 30 states plus Washington DC grant nurse practitioners full practice authority as of early 2026. In several of those, an NP may own the clinical entity outright.
In restrictive states the position differs sharply. Texas and California have been described as prohibiting NPs from owning medical practices entirely or from holding a majority interest.
A distinction owners repeatedly miss: full practice authority and ownership eligibility are separate questions. A state can grant an NP independent clinical practice and still restrict what entity they may own. Confirm both.
Registered nurses
In many states an RN can own the business. What an RN cannot do in any state is prescribe or independently order prescription-classified treatments.
So an RN-owned practice always requires a prescriber relationship — a physician or, where permitted, an NP or PA who performs the examination, writes the order, and carries clinical responsibility. That relationship is a structural dependency, and buyers examine it as one.
Non-clinical owners
Typically participate through an MSO alongside a physician-owned clinical entity. That structure is described below.
Two live examples of how quickly this moves
California’s AB 890 created a pathway for qualifying nurse practitioners to practise independently, with the relevant category taking effect in January 2026 — a genuine change in a state otherwise known for strict CPOM enforcement.
New York’s nurse practitioner practice-authority framework has carried a statutory sunset provision.
New York additionally restricts who may serve as a med spa’s medical director — an out-of-state physician cannot, and nurse practitioners face limits on holding the role.
What are the three ownership models?
Almost every compliant med spa uses one of three structures. Which applies is decided by your state and your licence, not by preference.
| Model | How it works | Typically used in | The buyer’s view |
|---|---|---|---|
| Direct ownership | The licensed owner — physician, or NP where permitted — owns the clinical entity outright | Permissive states with full practice authority | Simplest to diligence. The key question becomes transferability, if the owner is also the principal provider |
| Friendly PC + MSO | A physician owns the professional corporation holding the clinical practice; a separately owned MSO holds the business operations | Strict CPOM states | Standard for institutional buyers, but the documentation has to withstand scrutiny |
| MSO + medical director | A non-clinical owner runs the business; a contracted medical director provides clinical oversight | Common in the middle ground | Most likely to contain defects. The director relationship is examined closely |
Building the wrong structure is expensive in both directions
This is the point owners miss most often, and it runs both ways.
An operator in a permissive state who constructs an unnecessary friendly-PC arrangement spends significant money and delays their launch by months for no regulatory benefit whatsoever.
An operator in a strict state who skips it is exposed to enforcement, fee-splitting penalties, and — in California since SB 351 — attorney general attention.
Neither error announces itself at the time. Both surface in diligence.
What is an MSO, and what is a friendly PC?
A management services organisation provides non-clinical services to a physician-owned practice under a management services agreement. A friendly PC is the physician-owned professional corporation holding the clinical practice alongside it. The structure is legitimate, standard, and used by every consolidated healthcare vertical — but there is a line, and it is where transactions get complicated.
What each side may and may not do
The MSO may generally: provide premises, equipment, technology and non-clinical staff; handle marketing, scheduling, human resources and finance; and receive a fair-market-value management fee for those services.
The MSO generally may not: direct clinical decisions, determine treatment protocols, control clinical staffing decisions, or take compensation structured as a share of clinical revenue where the state restricts fee-splitting.
California’s SB 351, effective January 2026, drew that line more sharply — restricting management companies from participating in billing, coding, equipment selection and clinical staff oversight, and prohibiting private equity groups and hedge funds from interfering with professional judgement.
Management services agreements drafted before 2025 may need amendment to sit comfortably within it, and the requirements generally apply to arrangements that continue to operate rather than only to new ones.
What a buyer’s counsel will actually ask
The management services agreement is a primary diligence document, and the questions are consistent:
- Is the separation between clinical and business decision-making real, or nominal?
- Is the management fee defensible as fair market value?
- Is the physician owner of the PC genuinely exercising independent judgement, or is the arrangement an accommodation?
A structure that survives those three questions is an asset. One that does not is a negotiation you will conduct from a weak position.
The medical director — the role buyers examine first
For a great many practices this is the weakest structural link, and buyers know exactly where to look.
The pattern that causes trouble
The nominal medical director: a physician paid a modest monthly fee, named on the paperwork, and supervising nothing in practice.
Some states treat this as professional misconduct rather than a technicality. New York’s Office of Professional Medical Conduct has sustained enforcement attention on nominal medical director arrangements and undocumented good-faith examinations through 2024 to 2026.
What a buyer’s counsel wants to see
- A current written agreement with defined duties — not a template signed years ago and never revisited
- Evidence those duties are actually performed: chart review records, protocol approvals, documented availability
- Compensation consistent with the state’s fee-splitting rules
- The director appropriately licensed in your state
- Continuity — what happens to the relationship on a change of ownership
Documented duties that are not performed are worse than no documentation, because the file establishes what should have happened and the records establish that it did not.
The continuity question owners underestimate
If your medical director is a personal contact with no intention of continuing under a corporate owner, you have a transition problem — and it surfaces late in diligence, when replacing them quickly is difficult and the buyer knows it.
Who can inject? The delegation chain
Injector authority has two separate parts: who may decide a treatment is appropriate and order it, and who may administer it. Confusing the two is the most common compliance failure in medical aesthetics, and it is assessed alongside ownership in every diligence exercise.
| Provider | May decide and order | May administer |
|---|---|---|
| Physician (MD/DO) | Yes, in every state | Yes |
| Nurse practitioner | Usually, subject to state practice authority | Yes |
| Physician assistant | Generally yes, within delegated scope and supervising-physician protocols | Yes |
| Registered nurse | No | Yes, under delegation, after a good faith examination |
| LPN / LVN | No | Narrower than RN authority; varies considerably |
| Medical assistant, esthetician | No | Generally not for injectables |
Supervision proximity varies, and it matters
Some states require the supervising physician to be physically on site. Others accept a physician who is off site but reachable. California has been described as sitting at the stricter end, Washington at the more permissive.
This is not a paperwork distinction. Getting it wrong can render treatments unauthorised.
Standing orders have limits
A standing order can permit an authorised provider to administer follow-up treatment under a defined protocol.
It generally does not substitute for individual assessment of a new patient — which is the subject of the next section, and the single most important operational item on this page.
What is a good faith examination?
A good faith examination is an individualised assessment of a patient by a qualified prescriber before a prescription-classified treatment is ordered. It is the foundation of any lawful delegation. Where it is missing, downstream administration may be unauthorised regardless of whether the injector was properly licensed.
The failure pattern, and it is widespread
A registered nurse treats a first-time patient who has not been assessed by a prescriber.
The nurse is properly licensed. The product is properly sourced and stored. The delegation order exists as a document.
And the chain still fails — because the examination that authorises it did not happen.
Three details that recur
A delegation order does not replace the examination. It becomes valid only once the exam is complete, and it should be specific to that patient and that treatment rather than a reusable form applied across a patient base.
The requirement extends beyond neuromodulators. Other prescription-classified injectables and topicals generally carry the same requirement. Practices frequently treat their filler menu as lower risk; the requirement is generally the same.
Telehealth is accepted in some states, conditionally. Several states have moved toward accepting live, synchronous encounters for the examination — but a form completed without real-time provider interaction typically does not satisfy the requirement.
Why this belongs in an M&A publication
Good faith examination documentation is sampled in diligence.
A pattern of missing examinations is a compliance finding that attaches to historical treatments — which is precisely the category of inherited liability that produces an uncapped indemnity carve-out or a withdrawn buyer, rather than a negotiable price adjustment.
What changed in 2026?
The regulatory environment tightened materially, and the first half of 2026 alone produced significant developments in several major states.
California
SB 351 took effect on 1 January 2026, codifying and extending CPOM restrictions against private equity and hedge fund involvement and constraining what management companies may do. AB 1415 extended transaction reporting obligations.
Enforcement followed. The Attorney General settled with Aspen Dental in May 2026 over alleged corporate practice of dentistry violations — reported as $2 million in penalties, $300,000 in restitution and injunctive terms — and announced a settlement with Carbon Health in June 2026, reported as the first resolution directly targeting an MSO-PC structure under the doctrine.
Separately, AB 890’s independent-practice pathway for qualifying nurse practitioners took effect in January 2026.
New York
Continued enforcement attention on nominal medical director arrangements and undocumented good-faith examinations, alongside the practice-authority sunset flagged earlier on this page.
Elsewhere
Board-level guidance moved in several jurisdictions during the first half of 2026, including position statements and advisory opinions directed specifically at nurse-practitioner-owned operations.
The direction of travel
Consistent across all of it: more codification, more enforcement, and more attention to whether structural separation is real or merely documented.
For an owner planning an exit in the next two to three years, that is the argument for a structural review now rather than during exclusivity.
Five structural defects that reduce or kill a deal
Ranked by how often they cause a problem.
1. The nominal medical director. Named, paid a token fee, supervising nothing. Documented duties that are not performed are worse than no documentation.
2. Missing good faith examinations. Sampled in diligence, attaching to historical treatments, producing exactly the uncapped-indemnity conversation you do not want.
3. A management services agreement never reviewed since signing. Particularly in California post-SB 351, and particularly where it was adapted from a template written for a different state or a different sector.
4. Fee arrangements that resemble fee-splitting. Management fees calculated as a percentage of clinical revenue draw scrutiny in states restricting revenue-sharing with unlicensed parties.
5. Injector scope drift. The practice grows, the treatment menu expands, and someone begins performing a procedure outside their delegated scope. Nobody notices until the buyer’s counsel maps providers against treatments.
Each of these is fixable in advance. None is fixable quickly once a buyer has found it.
That asymmetry is the entire argument for reviewing structure twelve to twenty-four months before going to market.
The 50-State Ownership and Supervision Matrix
Last updated: [DATE] · Reviewed quarterly · [n] of 50 states published
Methodology
Each row cites the statute, board rule or advisory opinion it rests on, and carries the date it was last checked. Where a state’s position is genuinely unsettled — and several are — the row says so rather than offering a guess. States publish as they are verified rather than all at once.
| State | CPOM posture | Non-physician ownership | NP practice authority | Injector delegation | Good faith exam | Authority | Last verified |
|---|---|---|---|---|---|---|---|
| [Populate per §D. No row publishes without a cited authority.] |
Repeat caveat, rendered directly beneath the matrix: general background only, not legal advice, and not a complete statement of any state’s requirements. Confirm your own position with your state medical board, your state nursing board, and a healthcare attorney licensed in your state.
Frequently asked questions
Who can own a med spa? Licensed physicians can own in every US state. Whether a nurse practitioner, registered nurse or non-clinical owner can hold the clinical entity depends on the state’s corporate practice of medicine posture and its nurse practice act. In restrictive states, non-physicians participate through an MSO instead.
What is the corporate practice of medicine? A state-law doctrine restricting unlicensed individuals and corporations from owning medical practices, employing physicians, or controlling clinical decisions. It is not federal law, and states differ substantially in how they define and enforce it.
Can a nurse practitioner own a med spa? In some states. Roughly 30 states plus Washington DC grant full practice authority, and several permit ownership of the clinical entity. Restrictive states generally require physician ownership. Note that practice authority and ownership eligibility are separate questions.
What is an MSO in a med spa? A management services organisation provides non-clinical services — administration, marketing, staffing support, facilities, technology — to a physician-owned practice under a management services agreement, allowing non-physician capital to participate while clinical decisions remain with licensed providers.
Can a registered nurse inject Botox? In most states an RN may administer neuromodulators, but only under delegation from a qualified prescriber and only after that prescriber has performed a good faith examination. An RN cannot prescribe, and generally cannot perform the initial assessment of a new patient.
Do I need a medical director? In most structures, yes — and a named director who does not actually supervise is the most common structural defect found in diligence. What matters is a current agreement with defined duties and documentary evidence that those duties are performed.
How does compliance affect what my med spa sells for? Structural and supervision defects surface in legal diligence and typically produce extended timelines, larger escrows, indemnity carve-outs, or a withdrawn buyer. Institutional buyers inherit the risk, so they either price it or refuse it.
